Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd. develops and commercializes minimally invasive microwave ablation (MWA) medical devices, with a focus on thyroid-related diseases and other soft tissue conditions. News about BDMD commonly covers sales of MWA needles and microwave therapeutic apparatuses, distributor and direct-customer activity, clinical education for physicians, and the company's geographic expansion beyond Mainland China.
Updates also include regulatory clearances in international markets, U.S. clinical-conference engagement, and product-development work tied to software, AI-assisted planning, and robotic surgical systems. Financial releases discuss revenue mix, gross margin, R&D spending, and the effects of market policy and pricing dynamics on the company's China business.
Baird Medical (NASDAQ: BDMD) announced clinical education programs in the U.S. and Japan to accelerate global adoption of its Microwave Ablation (MWA) technology for benign thyroid tumors. The company led advanced training at Columbia University and a workshop at Showa Medical University to standardize interventional thyroidology techniques and expand non-surgical patient options.
Baird Medical (NASDAQ: BDMD) concluded a Gynecological Microwave Ablation Masterclass in Shanghai on January 28, 2026, led by Dr. Xiaoming Gong. The program combined didactic lectures and live case observations to train physicians across Asia in the company's proprietary microwave ablation technology.
The event reinforces Baird Medical's focus on physician education, expansion of minimally invasive women's health treatments, and broader commercial presence, noting FDA 510(k) certification and use in over 30 U.S. hospitals and in more than 20 countries.
Baird Medical (NASDAQ: BDMD) announced a strategic partnership with Stonewood Key Capital on Jan 26, 2026 to accelerate global commercialization of its minimally invasive Microwave Ablation (MWA) technology. The agreement designates the Hainan Free Trade Port as a hub for cross-border operations, supply chain activity, and more efficient capital allocation. The partnership leverages the Free Trade Port's policies on cross-border capital flows and personnel mobility and uses an integrated "Capital – Base-Service" ecosystem to support expansion into thyroid and other soft tissue applications.
The company framed the deal as a strategic operational pivot to deepen its global footprint and support clinical adoption of its MWA solutions.
Baird Medical (NASDAQ: BDMD) participated at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 20, 2026, where leadership met with institutional investors and healthcare veterans.
Discussions emphasized Baird Medical's 2026 strategic priorities: accelerating its U.S. commercial footprint and expanding adoption of its minimally invasive Microwave Ablation (MWA) thyroid technologies. The company stated these engagements reinforced market interest in its differentiated MWA platform and confirmed alignment with investors on clinical and growth objectives. Management said it will focus on executing its operational roadmap to enhance shareholder value and broaden patient access to its technologies.
Baird Medical (NASDAQ: BDMD) announced on January 7, 2026 that it received official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam. The company executed a Pakistan product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI) under the professional guidance of Dr. Raza Raheem.
Vietnam registration expands Baird Medical's compliant footprint in Southeast Asia and supports its stated global commercialization strategy by enabling market entry and clinician access to its microwave ablation (MWA) technology.
Baird Medical (NASDAQ: BDMD) announced on Dec. 17, 2025 the establishment of a dedicated U.S. manufacturing base to support its global expansion.
The company said it partnered with California-based MPS Medical to create a centralized production hub in North America, shifting from an exporter model toward a comprehensive global medical technology provider. The facility is described as supplying Baird Medical's proprietary Microwave Ablation technologies to global markets and improving quality and supply chain efficiency. Recent commercial growth noted includes market penetrations in Indonesia and Malaysia.
Baird Medical (NASDAQ: BDMD) announced completion of an advanced Microwave Ablation (MWA) training session on Dec. 8, 2025 led by Dr. Emad Kandil.
The program trained Dr. Richard Harding of Arizona Endocrine Surgery with observation of three live MWA procedures, a hands-on component, and strategic planning for integrating MWA into his Phoenix practice. Dr. Harding received a Certificate of Completion, underscoring proficiency in MWA and supporting expanded patient access to non‑surgical thyroid treatment options in Arizona.
Baird Medical (NASDAQ: BDMD) named Mark Saxton as Chief Executive Officer of its U.S. subsidiary effective December 3, 2025. Mr. Saxton has more than 25 years of commercial leadership in medical devices and will lead U.S. sales, marketing, and market development as Baird Medical accelerates U.S. entry for its microwave ablation (MWA) platform.
His prior roles include scaling VNUS Medical Technologies (doubling U.S. revenue from $49M to > $100M before a $512M acquisition by Covidien), supporting NeuroPace through a $117M IPO, and repositioning Ceterix for a $105M acquisition by Smith + Nephew.
Baird Medical (NASDAQ: BDMD) announced its official launch into the Egyptian market on Nov 3, 2025 with a successful first microwave bone ablation at Ain Shams Specialized Hospital.
The procedure, performed by Dr. Amr Mahmoud, treated a 1 x 1.5 cm bone lesion in a 30-year-old male with left thigh pain and achieved full ablation and marked pain relief, illustrating the Baird MWA system's use in musculoskeletal applications beyond soft tissue.
Baird Medical (NASDAQ: BDMD) announced clinical adoption of its Microwave Ablation (MWA) system at Elk Medical, a private endocrinology practice in Brooklyn, New York, on Oct. 27, 2025. Dr. Kazeem performed nine MWA procedures treating large thyroid nodules as a non-surgical alternative. The clinic reported that these initial procedures have been successfully reimbursed by Medicare, which the company described as an encouraging early step toward broader patient access and potential economic viability for MWA therapy in a key U.S. market.